Loading...
XNYS
EW
Market cap45bUSD
May 29, Last price  
77.73USD
1D
1.40%
1Q
8.53%
Jan 2017
148.90%
Name

Edwards Lifesciences Corp

Chart & Performance

D1W1MN
XNYS:EW chart
No data to show
P/E
10.92
P/S
8.38
EPS
7.12
Div Yield, %
—
Shrs. gr., 5y
-1.20%
Rev. gr., 5y
4.58%
Revenues
5.44b
-9.41%
997,900,0001,037,000,0001,091,100,0001,237,700,0001,321,400,0001,447,000,0001,678,600,0001,899,600,0002,045,500,0002,322,900,0002,493,700,0002,963,700,0003,435,300,0003,722,800,0004,348,000,0004,386,300,0005,232,500,0005,382,400,0006,004,800,0005,439,500,000
Net income
4.17b
+197.68%
79,300,000130,500,000113,000,000128,900,000229,100,000218,000,000236,700,000293,200,000391,700,000811,100,000494,900,000569,500,000622,100,000722,200,0001,046,900,000823,400,0001,503,100,0001,521,900,0001,402,400,0004,174,600,000
CFO
542m
-39.46%
136,800,000230,800,000210,200,000153,200,000165,300,000251,400,000314,500,000373,800,000472,700,0001,022,300,000549,700,000704,400,0001,000,700,000926,800,0001,179,400,0001,054,300,0001,732,100,0001,218,200,000895,800,000542,300,000
Earnings
Jul 22, 2025

Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
URL
https://www.edwards.com/
IPO date
Mar 27, 2000
Employees
17,300
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
5,439,500
-9.41%
6,004,800
11.56%
5,382,400
2.86%
Cost of revenue
2,170,500
4,276,200
3,593,200
Unusual Expense (Income)
NOPBT
3,269,000
1,728,600
1,789,200
NOPBT Margin
60.10%
28.79%
33.24%
Operating Taxes
152,100
198,700
245,500
Tax Rate
4.65%
11.49%
13.72%
NOPAT
3,116,900
1,529,900
1,543,700
Net income
4,174,600
197.68%
1,402,400
-7.85%
1,521,900
1.25%
Dividends
Dividend yield
Proceeds from repurchase of equity
(1,159,400)
(879,600)
(1,580,700)
BB yield
2.61%
1.89%
3.39%
Debt
Debt current
46,800
49,800
25,500
Long-term debt
778,900
767,900
760,800
Deferred revenue
Other long-term liabilities
810,600
778,400
797,600
Net debt
(3,458,100)
(1,410,700)
(1,668,000)
Cash flow
Cash from operating activities
542,300
895,800
1,218,200
CAPEX
(282,400)
(266,300)
(264,800)
Cash from investing activities
2,312,900
173,800
252,300
Cash from financing activities
(983,000)
(711,000)
(1,584,500)
FCF
3,691,600
817,300
1,305,600
Balance
Cash
3,975,900
1,644,500
1,215,300
Long term investments
307,900
583,900
1,239,000
Excess cash
4,011,825
1,928,160
2,185,180
Stockholders' equity
13,641,800
9,469,500
7,981,400
Invested Capital
7,585,075
6,289,440
5,014,220
ROIC
44.93%
27.07%
32.95%
ROCE
28.19%
21.04%
24.85%
EV
Common stock shares outstanding
599,300
609,400
624,200
Price
74.03
-2.91%
76.25
2.20%
74.61
-42.41%
Market cap
44,366,179
-4.52%
46,466,750
-0.23%
46,571,562
-43.05%
EV
40,972,579
45,125,450
44,903,562
EBITDA
3,424,200
1,873,500
1,928,800
EV/EBITDA
11.97
24.09
23.28
Interest
19,800
17,600
19,200
Interest/NOPBT
0.61%
1.02%
1.07%